Barclays cut shares of Hologic (NASDAQ:HOLX) from an overweight rating to an equal weight rating in a research note released on Wednesday morning, Marketbeat reports. They currently have $43.00 target price on the medical equipment provider’s stock, down from their prior target price of $50.00. The analysts noted that the move was a valuation call.

Several other equities research analysts have also weighed in on the company. BTIG Research reiterated a buy rating and issued a $47.00 price objective on shares of Hologic in a research note on Thursday, August 2nd. BidaskClub lowered Hologic from a hold rating to a sell rating in a research note on Friday, May 25th. Needham & Company LLC upped their price objective on Hologic from $43.00 to $48.00 and gave the company a buy rating in a research note on Wednesday, August 1st. Bank of America upped their price objective on Hologic from $44.00 to $47.00 and gave the company a buy rating in a research note on Wednesday, August 1st. Finally, Deutsche Bank lowered their price objective on Hologic from $45.00 to $43.00 and set a hold rating on the stock in a research note on Monday, August 20th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and eight have issued a buy rating to the company’s stock. The company presently has a consensus rating of Hold and an average target price of $44.87.

Shares of HOLX opened at $38.45 on Wednesday. Hologic has a 12-month low of $35.10 and a 12-month high of $45.09. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.99 and a current ratio of 1.29. The stock has a market cap of $10.54 billion, a P/E ratio of 18.94, a PEG ratio of 1.77 and a beta of 0.65.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Tuesday, July 31st. The medical equipment provider reported $0.58 earnings per share for the quarter, beating the consensus estimate of $0.56 by $0.02. Hologic had a positive return on equity of 22.18% and a negative net margin of 2.47%. The company had revenue of $824.00 million for the quarter, compared to analyst estimates of $800.14 million. analysts anticipate that Hologic will post 2.24 EPS for the current fiscal year.

Institutional investors and hedge funds have recently made changes to their positions in the company. Piedmont Investment Advisors LLC acquired a new position in shares of Hologic in the 2nd quarter worth approximately $127,000. Amussen Hunsaker Associates LLC acquired a new position in shares of Hologic in the 2nd quarter worth approximately $159,000. Synovus Financial Corp acquired a new position in shares of Hologic in the 1st quarter worth approximately $164,000. Homrich & Berg acquired a new position in shares of Hologic in the 2nd quarter worth approximately $204,000. Finally, Granite Springs Asset Management LLC acquired a new position in shares of Hologic in the 2nd quarter worth approximately $206,000. 98.66% of the stock is currently owned by institutional investors and hedge funds.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. The company operates through five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

Featured Article: How Do You Calculate Return on Equity (ROE)?

Analyst Recommendations for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.